To further explore the relationship between GATA6 expression and patient outcome, and its predictive value, we analysed TMAs from patients included in the ESPAC-3 trial.7 Using a histoscore based on the proportion of reactive cells and staining intensity, GATA6 expression was low/undetectable in 37/313 (11.8%) tumours. The gene discussed is GATA6; the disease is neoplasm.